Posted: July 9, 2014 at 8:44 am
Sarasota Stem Cell Specialist Inject Knees for Bone on Bone as alliterative
http//:Geckojoiontandspine.com Using adipose and bone marrow stem cells combined as well as PRP or the growth factors from the blood she was able to avoid a knee replacement surgery for osteoarthr...
By: AskDoctorJL
See the original post:
Sarasota Stem Cell Specialist Inject Knees for Bone on Bone as alliterative - Video
Posted: July 9, 2014 at 8:44 am
Bench to Bedside: Mesenchymal Stem Cells and ARDS, Part 1 - Carolyn Calfee
http://www.ibiology.org/ibioeducation/taking-courses/bench-to-bedside/mesenchymal-stem-cells-acute-respiratory-distress-syndrome.html In Part 1, Dr. Calfee begins by explaining that acute...
By: iBioEducation
See the article here:
Bench to Bedside: Mesenchymal Stem Cells and ARDS, Part 1 - Carolyn Calfee - Video
Posted: July 9, 2014 at 8:44 am
Patient Testimonial 3
By: Plexus Neuro and Stem Cell Research Centre
Original post:
Patient Testimonial 3 - Video
Posted: July 9, 2014 at 3:57 am
By Marcus Johnson
Researchers at Brown University have found that adipose-derived human stem cells (ASCs) might be highly resistant to methotrexate (MTX), a common chemotherapy drug. ASCs can ultimately become bone and other vital tissues throughout the body, which could be key for researchers looking to protect bone tissue from the damage caused by MTX treatment. MTX, which is used to treat a number of different cancers including acute lymphoblastic leukemia, causes the loss of bone density and has an adverse effect on bone marrow derived stem cells.
Kids undergo chemotherapy at such an important time when they should be growing, but instead they are introduced to this very harsh environment where bone cells are damaged with these drugs, said Olivia Beane, a Brown University graduate student in the Center for Biomedical Engineering and lead author of the study. That leads to major long-term side effects including osteoporosis and bone defects. If we found a stem cell that was resistant to the chemotherapeutic agent and could promote bone growth by becoming bone itself, then maybe they wouldnt have these issues.
Beane examined how MTX affects stem cells and certain tissues in the body and said that the resistance of certain stem cells to the drugs toxicity could mean new possibilities in the drug development realm. The researchers are now looking to find a way to make their study practical for doctors that are treating patients suffering from cancer. The next step is to test ASC survival in animal trials, where researchers will determine how the cells fare in mice that are also hit with the chemotherapy drug.
The study was published in the journal, Experimental Cell Research.
See the original post:
Brown University Researchers Discover Chemo Resistant Stem Cells
Posted: July 9, 2014 at 3:57 am
Last week, the scientific journal Nature retracted two papers which claimed that skin cells could be turned into stem cells. PBS NewsHour interviewed lead author Dr. Charles Vacanti of Brigham and Womens Hospital about the studies in January.
Vacanti and scientists from the RIKEN Institute in Japan claimed that bathing adult mouse cells in a mild acid made the cells behave like embryonic stem cells. It appeared to be an inexpensive way to create stem cells without destroying an embryo.
Controversy surrounding embryonic stem cells has slowed research progress. While it is possible to make stem cells from other sources, doing so is costly and takes time. If true, the finding would have opened new avenues for stem cell-related research and therapies.
But other scientists could not recreate stimulus-triggered acquisition of pluripotency (STAP) cells. An investigation in April found that RIKEN Institute junior scientist Haruko Obokata had falsely identified some of the images in the study, and plagiarized some of the descriptions in the paper. The studies authors pointed to five more errors when the journal printed its retraction last week, including images that claimed to show two different things, but actually showed the same thing.
We apologize for the mistakes included in the Article and Letter, the authors wrote in a statement. These multiple errors impair the credibility of the study as a whole and we are unable to say without doubt whether the STAP-SC phenomenon is real.
Original post:
Scientific journal Nature retracts controversial stem cell papers
Posted: July 9, 2014 at 3:57 am
DFG Research Center and Cluster of Excellence at the TU Dresden
The molecular biosciences provide unique prospects to enhance tissue and organ regeneration. Our goal is to develop advanced treatments for haemato-oncological, neurodegenerative, diabetic, bone, and cardiovascular diseases.
Dresden has outstanding expertise in the life science disciplines (medicine, molecular cell- and developmental biology, stem cell research, genomics, proteomics, bioinformatics) and engineering (tissue engineering, biomaterials science, chemistry, nanotechnology), providing a fertile ground for a broad interdisciplinary effort towards developing regenerative therapies. Over 150 partners from science, economy, administration, culture, and finance from Biopolis, an innovative network for biomedical research. Scientific integration and synergy within the Biopolis is facilitated by the close location of participating institutes.
The DFG Research Center and Cluster of Excellence at the TU Dresden is capitalizing on basic and clinical research in regenerating model organisms and in patients to understand stem cell recruitment, activation, proliferation, homing and differentiation, and will apply this knowledge to control these cellular processes using genetics, surface engineering and micro devices in order to elicit regenerative responses.
Go here to read the rest:
Center for Regenerative Therapies Dresden - CRTD
Posted: July 9, 2014 at 3:57 am
Regenerative medicine is now Tim Bertrams work but in previous chapters of his career, he focused on drugs while working for large pharmaceutical companies such as Pfizer (NYSE:PFE), Smithkline Beecham Pharmaceuticals and Procter & Gamble (NYSE:PG).
Bertram left big pharma seven years ago to join Tengion (NASDAQ:TNGN), whose tissue regeneration technology was originally developed at Wake Forest Universitys Institute for Regenerative Medicine. But before joining Tengion, his pharma colleagues gave him a warning: This technology will not go anywhere for at least 25 years, recalled Bertram, who is now Tengions chief scientific officer and interim CEO.
Regenerative medicine has come a long way. In 2005, most regenerative medicine research was done in academic institutions, Bertram said. Now there are companies such as Tengion. Applications for the kidney have been estimated to be a $32 billion opportunity. The eye represents a $40 billion annual market. As for East Norriton, Pennsylvannia-based Tengion, the companys technology has orphan drug designation from the Food and Drug Administration and is now being studied in clinical trials for use in patients with bladder cancer.
Bertram was the keynote speaker Thursday at the Regenerative Medicine Roundtable, a conference coordinated by Nagoya University. The university, located in central Japan, sponsors an annual roundtable in Research Triangle Park showcasing some of Nagoyas research. Nagoya maintains a three-person technology transfer office near RTP with the goal of licensing the universitys intellectual property. Nagoyas research includes work that could lead to treatments for neurogenic bladder and prostate cancer.
If the market opportunities are apparent, what are the barriers to the technology? Bertram said that many people think the biggest barrier is money. But thats not necessarily the case. Bertram is a member of the Tissue Engineering International & Regenerative Medicine Society, or TERMIS. The group is scheduled to release results of a regenerative medicine survey at the TERMIS North America chapter meeting in December but Bertram gave an early peak at some of the findings. Academics, companies and venture capitalists were queried about the barriers to commercializing regenerative medicine. Companies believe theres a dearth of investment dollars. But venture capitalists did not rank the availability of money as a hurdle for regenerative medicine. VCs have money to invest but their concerns lie in translating this science into clinical applications.
Money is available, said Abner Mhashilkar, medical translational officer for the Wake Forest Institute for Regenerative Medicine. Before joining Wake Forest, Mhashilkar worked for venture capital firm Toucan Capital, which focuses on investments in stem cells and regenerative medicine. Mhashilkar said that from the venture capitalists standpoint, one of regenerative medicines investment hurdles is time. Venture capitalists would like to see a return three to five times their investment within five to six years. Thats a tough timeline for regenerative medicine to meet. But Mhashilkar said that the technology has progressed and investors are interested. Theyre willing to invest now if they can find the right opportunity.
In order to find funding, companies need to go beyond discussing the science and emphasize the commercial applications, Bertram said. If the story of the technology is not simple and clear, the investment opportunity wont be apparent.
It will be up to investors to decide whether regenerative medicine is a sound investment. The National Venture Capital Association on Thursday released a report that said life sciences investments are shifting from the United States to Europe and Asia, a move driven by the uncertainty and length of the Food and Drug Administrations approval process. The investment picture is cloudy but its clear that regenerative medicine technology was not 25 years away.
Its coming, Bertram said. Its here. I dont believe its going to be beyond my lifetime. At least I hope.
Follow this link:
TNGN's Bertram discusses regenerative medicine's potential
Posted: July 9, 2014 at 3:52 am
After Stem Cell Therapy - Patient Interview
Patient Interview with #39;Josh #39; after stem cell treatment with Dr Mike Belich of Integrative Medical Clinics. The benefits of stem cell therapy and Regenerative Medicine.
By: Integrative Medical Clinics
Read the original:
After Stem Cell Therapy - Patient Interview - Video
Posted: July 9, 2014 at 3:52 am
Who We Are at World Stem Cells, LLC
Advanced stem cell treatments offered by Would Stem Cells, LLC a patient management company for qualified patients at the medical facilities World Stem Cells Clinic, http://worldstemcells.com/clinic-team.html in Cancun provides an opportunity for a better quality of life. The clinic and laboratory were designed, built and are operated under the stringent guidelines as established by The International Cellular Medical Society (ICMS) and the US Federal Drug Administrations Good Tissue Practice (cGTP)regulations for pharmaceutical, biologics and clinical laboratories. The strict adherence to these established guidelines and policies guarantees the highest quality of clinical care and stem cell treatment safety for you.
What Is Done
World Stem Cells Clinics medical staff and clinical physicians will examine you and review all available medical records, radiology films, CT scans and other diagnostic information to assess if stem cell therapy will be a helpful primary treatment or adjunctive therapy for your specific condition.
Then, the medical doctors meet and confer with the research scientists for a pre-treatment planning meeting. This Stem cell treatment planning conference takes advantage of decades of the staffs clinical experience, your current condition, your available social support system, full review of your medical history as well as an inclusion and consideration of any recently published research literature on stem cell treatments. In other words, you are provided a detailed, systematic and entirely unique treatment care plan for his or her needs.
Creating the best treatment
Sorry, they do not perform a one or two day treatment as it would not be medically sound and could not provide the benefits or safety that the World Stem Cells Clinic treatment schedule gives (please do not be fooled). Your Stem Cell Treatment at World Stem Cells Clinic takes 5 days to complete as the treatments are comprehensive and designed to maximize the benefits and safety you derive from the process.
How Is It Done
The World Stem Cells Clinics team harvest autologous stem cells from your own bone marrow, adipose (fat) tissue or circulating stem cells, within your bloodstream. They also offer allogeneic stem cells from other donors. These cells are harvested in the same way and under the same conditions. They are simply obtained from a donor as opposed to from you. They do not utilize fetal or laboratory-cultured embryonic stem cells. They chose not to use these sources of stem cells to prevent potential complications from contamination or side effects and adverse events such as graft versus host disease (GVHD).
After collection, your stem cells are tested and processed at the state-of-the-art and Good Tissue Practice (cGTP) laboratories. Data regarding the source of your stem cells, the amount harvested, and other information is recorded to ensure proper transfusion of your own cell or those of a chosen donor.
View post:
Stem Cells Treatments - World Stem Cells ClinicStem Cell ...
Posted: July 9, 2014 at 3:52 am
A young paraplegic woman who underwent spinal stem cell therapy developed a growth in her back made up of nasal cells eight years later.
The team from the University of Iowa Hospitals and Clinics that removed and investigated the growth has reported the anomaly in a paper published in the Journal of Neurosurgery: Spine. Although the case is a rare occurrence (the first of its kind, that we know of) the authors admit this may simply be because patients that undergo therapy are not monitored long enough, and either way it provides ample evidence attesting to our lack of understanding around programming and controlling stem cell proliferation and differentiation post-transplant.
Human trials for this type of therapy are still at the very early stages, but animal trials have had some promising results. Several different types of cells have been experimented with for implantation including schwann cells (these surround nerves and sometimes grow on the spinal cord post-injury), foetal neural cells (with successes in rat studies) andnasal olfactory ensheathing cells (these are extracted from the lining of the nose and were the ones used in this particular case study).
The patient in question was just 18 years old when she suffered an injury during a car accident. She had been paraplegic for three years when she opted to undergo surgery, implanting olfactory mucosal cells into the injury site. These cells originate in the roof of the nasal cavity and have the ability to take on the characteristics of other cells in the body because they are partially made up of progenitor cells (adult stem cells). They also contain olfactory ensheathing cells, often used in spinal cord therapy trials. This is all despite, as the authors note, the fact that: "the ability of these cell types to differentiate into organised neural tissue in humans or support new neural growth in humans in the setting of spinal cord injury is unclear."
The location of the transplantation was not divulged in the Spine paper, but the New Scientist reports that it was carried out as part of an early stage trial in the Hospital de Egas Moniz in Lisbon, Portugal. In a paper, the Lisbon team revealed that out of 20 candidates, 11 regained some sensation and one person's paralysis actually worsened.
The woman's therapy did not flag up any issues at the time of implantation, but eight years down the line she complained of worsening back pain that had already been ongoing for a year. Scans at the University of Iowa Hospitals and Clinics revealed a mass, thick like mucus and surrounded by fibrous walls, on the spinal cord, at the site of the cell implantation. The investigators explain that the mass was made up "mostly of cysts lined by respiratory epithelium, submucosal glands with goblet cells, and intervening nerve twigs". Nasal elements were growing.
The mass was pressing against the spinal cord, causing the patient discomfort and threatening her spine. When it was extracted, the team could confirm it came from the neural stem-like cells implanted eight years earlier, because the cysts contained a network of non-functioning nerves that were separate from the spine (suggesting they were new) and bone.
"The presence of these nerves within the mass indicates the capacity of olfactory mucosa to support nerve fibre regeneration or new nerve formation," write the team.
In total, the mass was made up of two major parts, measuring 1.4 x 0.8 x 0.7 cm and 1.6 x 1.3 x 0.7 cm. When they were removed, the patient's pain immediately subsided.
These kinds of trials have been ongoing for years, but the fears have been that stem cells -- which have the ability to turn into any cell in the body if programmed to -- could just as easily mutate into something that is not intended, and create tumours in the long term.
Link:
Stem cell therapy caused nasal tumour on paraplegic's back
